ArticleCureus2026
Profound Synergistic Bradycardia: Pharmacokinetic Consequences of Paxlovid-Mediated CYP3A4 and CYP2D6 Inhibition on Ranolazine, Diltiazem, and Metoprolol.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paxlovid, a codrug of nirmatrelvir/ritonavir, has established itself in the COVID-19 treatment arsenal due to numerous studies documenting clinical efficacy regardless of vaccination status. The ritonavir component, however, is a strong CYP3A4 and strong-to-moderate CYP2D6 inhibitor, reducing the clearance of many cardiovascular drugs. While existing literature documents symptomatic bradycardia from Paxlovid, and single- or dual-drug regimen, a case report of a triple-drug regimen of ranolazine, diltiazem, and metoprolol - utilizing both CYP3A4 and CYP2D6 pathways - is rare. Here we present the case of an 81-year-old female on ranolazine, diltiazem, and metoprolol who developed profound bradycardia (atrial fibrillation with slowed ventricular response) and hypotension due to reduced clearance of these drugs from CYP inhibition. An 81-year-old female with atrial fibrillation, coronary artery disease, and heart failure was prescribed Paxlovid after testing positive for COVID-19 in the outpatient setting. She subsequently experienced rapid hemodynamic collapse with a heart rate of 41 bpm (from baseline ~66 bpm) and blood pressure of 57/36 mmHg. She was intubated and initiated on multi-drug inotropic support (isoproterenol, dopamine, and epinephrine). Medication reconciliation revealed a home regimen of ranolazine (1000 mg BID), diltiazem (180 mg BID), and metoprolol tartrate (25 mg BID) - all primary CYP 3A4/2D6 substrates. The patient was successfully weaned off of vasopressors and extubated within 48 hours following Paxlovid discontinuation and supportive care. She maintained hemodynamic stability and was discharged the following day. This case demonstrates that the ritonavir component of Paxlovid can result in the supratherapeutic serum accumulation of ranolazine, diltiazem, and metoprolol through a dual-CYP 3A4 and 2D6 pathway inhibition, leading to a life-threatening bradycardic and hypotensive crisis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.